IGF1R beta Monoclonal Antibody (24-31) | Invitrogen MA5-13802 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

IGF1R beta Monoclonal Antibody (24-31)

catalog :

MA5-13802

quantity :

500 µL

price :

US 436.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

24-31

reactivity :

human

application :

immunocytochemistry, immunoprecipitation

citations: 23

Reference
Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, et al. Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. Cancer Sci. 2014;105:1591-600 pubmed publisher
Mountzios G, Aivazi D, Kostopoulos I, Kourea H, Kouvatseas G, Timotheadou E, et al. Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS ONE. 2014;9:e91407 pubmed publisher
Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS ONE. 2013;8:e54048 pubmed publisher
Fidler M, Basu S, Buckingham L, Walters K, McCormack S, Batus M, et al. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012;32:1705-10 pubmed
Scheipl S, Froehlich E, Leithner A, Beham A, Quehenberger F, Mokry M, et al. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study. Histopathology. 2012;60:999-1003 pubmed publisher
Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, et al. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast. 2010;19:370-6 pubmed publisher
Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009;20:842-9 pubmed publisher
Takahari D, Yamada Y, Okita N, Honda T, Hirashima Y, Matsubara J, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology. 2009;76:42-8 pubmed publisher
Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita N, Kato K, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 2008;14:3022-9 pubmed publisher
Hudelist G, Wagner T, Rosner M, Fink Retter A, Gschwantler Kaulich D, Czerwenka K, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer. 2007;14:1053-62 pubmed
Harris L, You F, Schnitt S, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13:1198-207 pubmed
Lopez Knowles E, Hernandez S, Kogevinas M, Lloreta J, Amorós A, Tardon A, et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res. 2006;12:6029-36 pubmed
Motoi N, Kishi K, Fujii T, Tsuboi E, Ohashi K, Yoshimura K. Multiple bronchioloalveolar carcinomas in acromegaly: a potential role of insulin-like growth factor I in carcinogenesis. Lung Cancer. 2006;54:247-53 pubmed
Stefano J, Correa Giannella M, Ribeiro C, Alves V, Massarollo P, Machado M, et al. Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol. 2006;12:3821-8 pubmed
Henriksen K, Rasmussen B, Lykkesfeldt A, Møller S, Ejlertsen B, Mouridsen H. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol. 2007;60:397-404 pubmed
Kostler W, Hudelist G, Rabitsch W, Czerwenka K, Muller R, Singer C, et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol. 2006;132:9-18 pubmed
Langner C, Ratschek M, Rehak P, Tsybrovskyy O, Zigeuner R. The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology?. BJU Int. 2005;95:310-4 pubmed
Budde A, Schneiderhan Marra N, Petersen G, Brüne B. Retinoblastoma susceptibility gene product pRB activates hypoxia-inducible factor-1 (HIF-1). Oncogene. 2005;24:1802-8 pubmed
Singer C, Hudelist G, Lamm W, Mueller R, Czerwenka K, Kubista E. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer. 2004;11:861-9 pubmed
Schips L, Zigeuner R, Ratschek M, Rehak P, Ruschoff J, Langner C. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol. 2004;122:931-7 pubmed
Zhang P, Furth E, Cai X, Goldblum J, Pasha T, Min K. The role of beta-catenin, TGF beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol. 2004;35:670-4 pubmed
Keehn C, Saeed S, Bickle K, Khalil F, Morgan M. Expression of insulin-like growth factor-I receptor in primary cutaneous carcinomas. J Cutan Pathol. 2004;31:368-72 pubmed
Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci. 2003;48:1972-8 pubmed

product information

Product Type :

Antibody

Product Name :

IGF1R beta Monoclonal Antibody (24-31)

Catalog # :

MA5-13802

Quantity :

500 µL

Price :

US 436.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

ELISA: Assay-dependent, Immunocytochemistry: 1:10-1:100, Immunoprecipitation: 2 µg/mL

Species :

Human

Clone :

24-31

Isotype :

IgG1

Storage :

4° C

Description :

IGF-1R (Insulin-like Growth Factor-1 Receptor) consists of alpha- and beta-subunits, which are disulfide-linked in a beta-alpha-alpha-beta configuration in the mature receptor. The alpha-subunit is completely extracellular, while the beta-subunit spans the membrane and the intracellular portion has intrinsic tyrosine kinase activity.

Immunogen :

IGF-1R/3T3 mouse fibroblasts transfected with human type I IGF-receptor cDNA

Format :

Liquid

Applications w/Dilutions :

ELISA: Assay-dependent, Immunocytochemistry: 1:10-1:100, Immunoprecipitation: 2 µg/mL

Aliases :

A330103N21Rik; CD221; D930020L01; hyft; IGF1R; IGF-1R; IGF-I receptor; IGFIR; IGFIRC; IGFR; Igfr1; insulin like growth factor 1 receptor; insulin-like growth factor 1 receptor; Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain; Insulin-like growth factor I receptor; JTK13; line 186; soluble IGF1R variant 1; soluble IGF1R variant 2